Oct 03rd 2012 - Edison Investment Research today published a report on Viropharma entitled "Rising On Cinryze". In summary, the report says:
ViroPharma has moved on quickly and effectively from a setback in April 2012 when generic versions of Vancocin flooded the US market. Key to the rebound has been ongoing success and burgeoning expectations for Cinryze, the only prophylactic agent for hereditary angioedema (HAE) in the US – net sales are expected to exceed $325m in 2012 and ViroPharma is now guiding to >$700m peak annual global sales of the drug and 2015 total revenues of $700m-$800m. We view 2.5x 2015 EV/sales as undemanding and see further upside potential from the pipeline.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »